Physician profile
Romy Chamoun
NPI 1699302646
$1,192.57
in general payments reported to CMS, 2019-2025
11 companies · $720 in 2025
The $720 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $113 · 2023: $98.43 · 2024: $158 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.63 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $412.45 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $257.16 | 2022-2025 | Entyvio |
| Kestra Medical Technology Services, INC. | $123.88 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals Lp | $103.85 | 2021 | |
| Gilead Sciences, INC. | $96.94 | 2022 | |
| Abbvie INC. | $50.51 | 2024-2025 | Viberzi, Linzess, Creon |
| Medtronic, INC. | $48.03 | 2023 | Interstim |
| Boston Scientific Corporation | $30.08 | 2023 | |
| Mallinckrodt Hospital Products INC. | $27.41 | 2025 | Terlivaz |
| Novo Nordisk INC | $21.94 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $20.32 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romy Chamoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.